Physician profile
Matthew Furman
NPI 1013913813
$2,460.63
in general payments reported to CMS, 2019-2025
19 companies · $931 in 2025
The $931 reported for 2025 was more than what 94% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.21 · 2020: $195 · 2021: $376 · 2022: $108 · 2023: $210 · 2024: $574 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $1,532.23 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $284.25 | 2023-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.97 | 2020-2025 | Relistor |
| Bioventus LLC | $71.17 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $61.03 | 2025 | |
| Alnylam Pharmaceuticals INC. | $56.76 | 2022 | |
| Spr Therapeutics, INC | $55.73 | 2025 | Sprint Pns System |
| Abbott Laboratories | $42.70 | 2021-2025 | Proclaim |
| Boston Scientific Corporation | $38.03 | 2019 | |
| Biodelivery Sciences International, INC. | $25.67 | 2021 | |
| Averitas Pharma INC. | $24.37 | 2024 | Qutenza |
| Valinor Pharma, LLC | $23.32 | 2025 | Movantik |
| Protega Pharmaceutials INC | $21.60 | 2023 | Roxybond |
| Nevro Corp. | $18.92 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $14.06 | 2020 | |
| Abbvie INC. | $14.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.61 | 2023 | Farxiga |
| Fidia Pharma USA INC. | $12.84 | 2023 | Triluron, Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.